Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMINENT: Felzartamab vs Tacrolimus in Primary Membranous Nephropathy
NCT06962800Phase 3Recruiting
- Sponsor
- Biogen
- Start
- May 2025
- Primary completion
- Jan 2030
- Countries
- 11
01
Overview
A Phase 3 trial of felzartamab in primary membranous nephropathy (PMN), sponsored by Biogen. Started May 2025; status: recruiting.
02
Drugs
felzartamab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT06962800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962800.